Alireza Ghajar
Greenville, NCNPI 1104448125
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.7%), travel and lodging and education — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Medtronic at 33.4% of the total. 2025 is the largest year on record at $10,073, more than ten times the $198 reported in 2023.
Across 174 payments — averaging $87.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Biotronik Inc.$5K
- Abbott$2K
- Abiomed$1K
- Boston Scientific$278
- E.r. Squibb & Sons, L.L.C.$245
- plus $1K from 17 others
What the payments were for
- Travel & lodging$6,62243%
- Food & beverage$8,22454%
- Education$4573%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 53 | $5,115 |
| Biotronik Inc. | 39 | $4,802 |
| Abbott | 27 | $2,207 |
| Abiomed | 15 | $1,297 |
| Boston Scientific | 6 | $278 |
| E.r. Squibb & Sons, L.L.C. | 2 | $245 |
| Amgen | 4 | $214 |
| Atricure, Inc. | 2 | $212 |
| Vital Connect, Inc | 2 | $166 |
| Shockwave Medical, Inc | 1 | $135 |
| Novo Nordisk | 2 | $117 |
| Terumo Medical Corporation | 1 | $105 |
| Novartis | 5 | $96 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $88 |
| Bayer | 3 | $50 |
| Lantheus Medical Imaging, Inc. | 2 | $50 |
| Cardiva Medical, Inc. | 1 | $24 |
| Janssen Scientific Affairs, LLC | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Cvrx, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MERLIN@HOME$929
- PAMIRA$844
- Selectra$664
- Acticor 7 VR-T DX$597
- Solia$396
- AMVIA EDGE$396
- ENSITE$270
- CAMZYOS$245
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$164
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$135
- BioMonitor$128
- Rivacor 7 DR-T$125
- AMPLATZER AMULET$119
- COBALT DR MRI SURESCAN$106
- Optitorque$105
- ANGIO-SEAL$105
- GlideWire$105
- METACROSS OTW$105
- AVEIR$104
- Baylis Medical Company Radiofrequency Puncture Generator$104
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 50 | $45,529 |
| EliquisApixaban | 35 | $35,911 |
| Repatha SureclickEvolocumab | 28 | $18,314 |
| JardianceEmpagliflozin | 14 | $16,390 |
| FarxigaDapagliflozin Propanediol | 13 | $14,189 |
| BrilintaTicagrelor | 13 | $9,311 |
| Metoprolol Succinate | 87 | $946 |
| Ezetimibe | 51 | $840 |
| Atorvastatin Calcium | 35 | $460 |
| Carvedilol | 25 | $288 |
| Lisinopril | 42 | $282 |
| Metoprolol Tartrate | 31 | $240 |
| Spironolactone | 29 | $192 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 25 | $187 |
| ClopidogrelClopidogrel Bisulfate | 11 | $173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $96 | $45,52950 claims |
| AstraZenecaFarxiga, Brilinta | $16 | $23,50026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in North Carolinaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.